Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04956575 · ClinicalTrials.gov registry record · Phase 1
A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults
A Phase 1 study, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 1
- Development phase
- 885
- Enrollment target
NCT04956575: Completed Phase 1 study, sponsored by ModernaTX.
NCT04956575 is a Phase 1 study that has completed, run by ModernaTX. The registered enrollment target is 885 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (1375% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04956575, a Phase 1 study, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 885 participants
- Enrollment target
Study Summary
The study comprises 3 parts: Phase 1/2, Phase 2 Northern Hemisphere (NH), and Phase 2 extension. The primary objective of this study is to evaluate the safety, reactogenicity, and humoral immunogenicity of mRNA-1010 vaccine.
Primary Outcome
Solicited ARs (local and systemic) were collected in the electronic diary (eDiary). Local ARs included: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, body temperature (potentially fever), and chills. Solicite
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL mRNA-1010
- BIOLOGICAL Active Comparator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 885 participants |
| Start Date | 2021-07-06 |
| Est. Completion | 2022-09-27 |
| Phase | Phase 1 |
What the finished NCT04956575 record still lists
NCT04956575 is an interventional study that assigns participants to a tested intervention. The registered 885 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (1375% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04956575 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04956575 about?
NCT04956575 is a clinical study titled "A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults". The study comprises 3 parts: Phase 1/2, Phase 2 Northern Hemisphere (NH), and Phase 2 extension. The primary objective of this study is to evaluate the safety, reactogenicity, and humoral immunogenicity of mRNA-1010 vaccine.
What is the current status of trial NCT04956575?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 885 participants. The study started on 2021-07-06. Estimated completion is 2022-09-27.
What interventions are being tested in trial NCT04956575?
The interventions under investigation include: Placebo (BIOLOGICAL), mRNA-1010 (BIOLOGICAL), Active Comparator (BIOLOGICAL).
Who is sponsoring clinical trial NCT04956575?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04956575's enrollment target sits among peer trials
885 11th of 2000 higher than 1,990 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07196748 · 882 participants · Phase 3
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
- NCT03564340 · 890 participants · Phase 1
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- NCT05174286 · 880 participants · NA
Community Health Workers United to Reduce Colorectal Cancer and Cardiovascular Disease Among People at Higher Risk
- NCT05454280 · 880 participants · Phase 3
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI